Detalles de la búsqueda
1.
Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer.
Int J Mol Sci;
24(22)2023 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38003273
2.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med;
373(17): 1627-39, 2015 Oct 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-26412456
3.
Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report.
BMC Cancer;
16: 118, 2016 Feb 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-26887807
4.
Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?
Int J Mol Sci;
16(1): 747-57, 2014 Dec 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-25561229
5.
Healthcare Costs and Resource Utilisation of Italian Metastatic Non-Small Cell Lung Cancer Patients.
Cancers (Basel);
16(3)2024 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38339345
6.
Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry Experience.
Diagnostics (Basel);
14(10)2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38786322
7.
Multicenter institutional experience of surgically resected thymic epithelial tumors (TETs): an observational report on behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone).
Ann Surg Oncol;
20(9): 2958-63, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23709100
8.
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease.
BMC Cancer;
13: 542, 2013 Nov 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24215543
9.
Malignant Pleural Mesothelioma: Preliminary Toxicity Results of Adjuvant Radiotherapy Hypofractionation in a Prospective Trial (MESO-RT).
Cancers (Basel);
15(4)2023 Feb 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36831400
10.
The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer.
Life (Basel);
13(9)2023 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37763318
11.
High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis.
Front Immunol;
13: 866561, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35493483
12.
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial.
J Thorac Oncol;
17(9): 1086-1097, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35659580
13.
Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma.
Front Pharmacol;
12: 672233, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34456717
14.
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy.
Expert Rev Anticancer Ther;
21(8): 809-817, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33905667
15.
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors.
Front Immunol;
12: 672219, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34122429
16.
Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Front Immunol;
12: 697298, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34858389
17.
Unveiling mutational dynamics in non-small cell lung cancer patients by quantitative EGFR profiling in vesicular RNA.
Mol Oncol;
15(9): 2423-2438, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33942501
18.
The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer.
Front Oncol;
11: 669839, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34017688
19.
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
J Clin Oncol;
39(7): 723-733, 2021 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33449799
20.
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
Lung Cancer;
142: 47-50, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32088605